Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
8.45
-0.54 (-6.01%)
At close: Feb 21, 2025, 4:00 PM
8.44
-0.01 (-0.12%)
After-hours: Feb 21, 2025, 6:54 PM EST
Indivior Revenue
In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth. Indivior had revenue of $298.00M in the quarter ending December 31, 2024, with 1.71% growth.
Revenue (ttm)
$1.19B
Revenue Growth
+8.69%
P/S Ratio
0.91
Revenue / Employee
$1,020,619
Employees
1,164
Market Cap
1.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
INDV News
- 2 days ago - Indivior PLC (INDV) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat - Benzinga
- 2 days ago - UK's Indivior forecasts 17% decline in 2025 revenue - Reuters
- 2 days ago - Indivior Announces FY and Q4 2024 Financial Results - PRNewsWire
- 10 days ago - Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes - PRNewsWire
- 3 months ago - Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 - PRNewsWire
- 3 months ago - Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior - PRNewsWire
- 4 months ago - Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month - PRNewsWire